← Back to Search

Oxygen Therapy

Supplemental oxygen (3 liters per minute) for Pulmonary Hypertension (SOPHIE Trial)

Phase 1 & 2
Waitlist Available
Led By Daniel Edmonston, MD, MHS
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 1, 2, and 3
Awards & highlights

SOPHIE Trial Summary

This trial aims to see if giving extra oxygen during dialysis can help people with high blood pressure in the lungs and low oxygen levels during dialysis.

Who is the study for?
This trial is for individuals who have pulmonary hypertension (high blood pressure in the lungs) and experience low oxygen levels during hemodialysis, a treatment for kidney failure. Specific eligibility details are not provided.Check my eligibility
What is being tested?
The study is testing whether giving extra oxygen during hemodialysis can help people with lung-related high blood pressure compared to those breathing normal room air.See study design
What are the potential side effects?
Potential side effects may include dry or bloody nose, morning headaches, tiredness, and irritation from the oxygen delivery system. However, specific side effects related to this trial's interventions are not detailed.

SOPHIE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 1, 2, and 3
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 1, 2, and 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change daily hypoxemia burden
Secondary outcome measures
Change in Montreal Cognitive Assessment (MoCA)
Change in six minute walk distance

SOPHIE Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Supplemental oxygen (3 liters per minute)Experimental Treatment1 Intervention
Participants will receive supplemental oxygen by oxygen concentrator delivered by nasal cannula at 3 liters per minute.
Group II: Supplemental oxygen (0.5 liters per minute)Experimental Treatment1 Intervention
Participants will receive supplemental oxygen by oxygen concentrator delivered by nasal cannula at 0.5 liters per minute.
Group III: Room airPlacebo Group1 Intervention
Participants will receive no supplemental oxygen.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oxygen
2013
Completed Phase 4
~12430

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,365 Previous Clinical Trials
3,420,634 Total Patients Enrolled
Daniel Edmonston, MD, MHSPrincipal InvestigatorDuke University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are prospective participants currently able to enroll in this medical study?

"According to details on clinicaltrials.gov, recruitment is no longer ongoing for this particular trial. Initial posting of the study took place on July 1st, 2024 and its most recent update was on March 18th, 2024. Despite this trial not seeking participants currently, it's worth noting that there are a total of 890 other trials actively pursuing candidates at present."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia
2024. "A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06327373.
All > Pulmonary Hypertension
~7 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top